ClinicalTrials.gg
RecruitingNCT07059650Updated Apr 1, 2026

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

A Phase 1/2 interventional study of DZD8586+R-CHOP and DZD8586+R-GemOx in Diffuse Large B-Cell Lymphoma, sponsored by Dizal Pharmaceuticals. Recruiting at 13 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Dizal Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China — 143 open to participants now, 165 under way, 31 of them phase 3. Lymphoma, Large B-Cell, Diffuse · China.

Planned enrollment
68th of 277
150 · median 59
Started
2025
with 36 others
Phase 1/2
41 of 306
20 open now
Primary completion
2030-10
later than 162 of 164 live
Registered
257th of 306
by date

Among the 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China, this one is the 68th largest by planned enrollment of the 277 interventional ones that give a count, is one of 37 that started in 2025, is one of 41 in phase 1/2, reaches primary completion later than 162 of the 164 other live ones, and was the 257th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

143 of the 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China are open now. Recruiting first, the newest first:

138 more — sign in →

All 143 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China, or all of them as a file.
02

Study summary

This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of adverse events. It will also measure the levels of DZD8586 in the body when combined with immunochemotherapy regimens.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort 1:

    1. Patients with confirmed DLBCL who have not received prior anti-lymphoma therapy.
    2. Disease stage II to IV by Ann Arbor Classification.
    3. ≥ 12 months.
  • Cohort 2, 3:

    1. Pathologically confirmed DLBCL patients who have received adequate treatment containing CD20 monoclonal antibody and anthracyclines (such as R-CHOP-like regimen).
    2. to first-line R-CHOP-like regimen.
    3. For patients who have received only one line of therapy, if the patient has not received stem cell transplantation, the investigator needs to assess as unsuitable or the patient refuses intensive chemotherapy and hematopoietic stem cell transplantation.
    4. Life expectancy ≥ 6 months.
  • Patients must also meet all of the following criteria to be included in this study:

    1. All patients must provide a signed and dated written prior to any study-specific procedure, sampling, and analysis.
    2. Patients must be ≥ 18 years of age at the time of informed consent.
    3. status score of 0 to 2.
    4. Presence of at least one radiologically in 2 perpendicular directions as assessed by CT or MRI and a positive lesion on PET/CT scan consistent with a tumor site identified by CT or MRI.
    5. Adequate bone marrow hematopoietic reserve and organ function.
    6. No uncontrolled medical complications.
    7. Patients should be able to follow the relevant requirements of this study for medication and follow-up.
    8. Willing to comply with restrictions.

Exclusion criteria

Exclusion Criteria:

  • Cohort 2, 3:

    a. Hematopoietic stem cell transplantation, cell therapy, or gene therapy within 90 days prior to first dose. Radiation therapy within 14 days prior to first dose. Chemotherapy and small-molecule targeted therapy were not terminated within 5 half-lives before the first dose; macromolecule drug therapy (such as antibody therapy) was not terminated within 28 days before the first dose.

  • All patients should not be included in this study if they have any of the following conditions:

    1. Indolent lymphoma-transformed DLBCL, primary mediastinal lymphoma, lymphoma involving the central nervous system, or DLBCL with MYC and BCL2 rearrangements.
    2. Prior use of BTK inhibitors.
    3. Vaccination with or viral vector vaccines within 4 weeks prior to enrollment.
    4. Currently taking vitamin K antagonists, taking 2 or more antiplatelet/anticoagulant drugs at the same time, drugs/herbs or supplements known to potently induce or inhibit enzyme activity, proton pump inhibitor drugs, anti-tumor traditional Chinese medicine or failing to meet the protocol-specified withdrawal time before administration in this study.
    5. Major surgery within 4 weeks or anticipated surgery after the start of this study. Or insufficiently recovered from any toxicity and/or complications of previous intervention.
    6. cardiac disorders. History of thrombotic diseases, stroke or intracranial hemorrhage within 6 months.
    7. Active infectious diseases.
    8. Intractable nausea and vomiting that cannot be well controlled by supportive treatment, chronic gastrointestinal diseases, dysphagia, or previous surgical resection of the intestinal segment may affect the adequate absorption of the drug.
    9. The patient has been diagnosed with other malignant diseases other than B-cell lymphoma within the past 2 years.
    10. Patients with to DZD8586 drug or other chemical analogues.
    11. Patients with severe or uncontrolled systemic diseases, including poorly controlled hypertension and active bleeding constitution.
    12. Serious medical or psychiatric illness that could affect participation in the study or could compromise the ability to consent
    13. Women who are pregnant or breastfeeding.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    DZD8586 combination therapy

    3 cohorts are included in this arm: Cohort 1: Treatment naïve DLBCL patients will receive DZD8586 at the protocol defined dose level, combined with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens for 6 cycles, and then DZD8586 as maintenance therapy for patients who achieved (complete response) CR or (partial response) PR after 6 cycles combination therapy. Cohort 2: Relapsed/refractory DLBCL patients will receive DZD8586 at the protocol defined dose level, combined with R-GemOx (rituximab, gemcitabine, and oxaliplatin) regimens for 8 cycles, and then DZD8586 as maintenance therapy for patients who achieved CR or PR after 8 cycles combination therapy. Cohort 3: Relapsed/refractory DLBCL patients will receive DZD8586 at the protocol defined dose level, combined with BR (bendamustine and rituximab) regimens for 6 cycles, and then DZD8586 as maintenance therapy for patients who achieved CR or PR after 6 cycles combination therapy.

    Drug: DZD8586+R-CHOP · Drug: DZD8586+R-GemOx · Drug: DZD8586+BR

Interventions

  • DrugDZD8586+R-CHOP

    Drug page: Birelentinib

    DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with R-CHOP (Rituximab: 375 mg/m2, IV, d1; Cyclophosphamide: 750 mg/m2, IV, d1; Doxorubicin: 50 mg/m2, IV, d1; Vincristine: 1.4 mg/m2, IV, d1; Prednisone: 100 mg, po, d1-5) in a 21-day cycle for 6 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.

  • DrugDZD8586+R-GemOx

    Drug page: Birelentinib

    DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with R-GemOx (Rituximab: 375 mg/m2, IV, d1; Gemcitabine: 1000 mg/m2, IV, d1; Oxaliplatin: 100 mg/m2, IV, d1) in a 21-day cycle for 8 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.

  • DrugDZD8586+BR

    Drug page: Birelentinib

    DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with BR (Bendamustine: 90 mg/m2, IV, d1-d2; Rituximab: 375 mg/m2, IV, d1) in a 21-day cycle for 6 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.

06

What researchers measure

Primary outcomes

  1. Part A: Incidence and severity of adverse events

    Time frame: Approximately 5 years

  2. Part B: Objective response rate (ORR)

    Time frame: Approximately 5 years

Secondary outcomes

  1. Part A: Objective response rate (ORR)

    Time frame: Approximately 5 years

  2. Part A: Complete response rate (CRR)

    Time frame: Approximately 5 years

  3. Part A: Time to response (TTR)

    Time frame: Approximately 5 years

  4. Part A: Duration of Response (DoR)

    Time frame: Approximately 5 years

  5. Part A: Progression-Free Survival (PFS)

    Time frame: Approximately 5 years

  6. Part A: Overall Survival (OS)

    Time frame: Approximately 5 years

  7. Part B: Incidence and severity of adverse events

    Time frame: Approximately 5 years

  8. Part B: Complete response rate (CRR)

    Time frame: Approximately 5 years

  9. Part B: Time to response (TTR)

    Time frame: Approximately 5 years

  10. Part B: Duration of Response (DoR)

    Time frame: Approximately 5 years

  11. Part B: Progression-Free Survival (PFS)

    Time frame: Approximately 5 years

  12. Part B: Overall Survival (OS)

    Time frame: Approximately 5 years

  13. Part A: Peak plasma concentration (Cmax) of DZD8586 and metabolite (DZ4581)

    Time frame: Up to 24 hours post dose

  14. Part A: Area under the plasma concentration versus time curve (AUC) of DZD8586 and metabolite (DZ4581)

    Time frame: Up to 24 hours post dose

  15. Part A: Time to peak concentration (Tmax) of DZD8586 and metabolite (DZ4581)

    Time frame: Up to 24 hours post dose

  16. Part A: Metabolite (DZ4581) to parent (DZD8586) ratio based on area under the plasma concentration versus time curve (MRAUC)

    Time frame: Up to 24 hours post dose

  17. Part A: Trough concentration at steady state (Css, min) of DZD8586 and metabolite (DZ4581)

    Time frame: Up to 24 hours post dose

  18. Part A: Apparent clearance at steady state (CLss/F) of DZD8586

    Time frame: Up to 24 hours post dose

  19. Part A: Accumulation index in area under the plasma concentration versus time curve (RACAUC) of DZD8586 and metabolite (DZ4581)

    Time frame: Up to 24 hours post dose

  20. Part A: Accumulation index in peak plasma concentration (RACCmax) of DZD8586 and metabolite (DZ4581)

    Time frame: Up to 24 hours post dose

07

Study locations

12 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Oct 2030, 62 months after the start.

Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's planned 62 months is below that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jul 11, 2025
StartActual
Aug 19, 2025
Primary completionEst.
Oct 2030
CompletionEst.
Oct 2030
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07059650
Responsible party
Sponsor
First posted
Jul 11, 2025
Start date
Aug 19, 2025
Primary completion
Oct 2030 (estimated)
Completion
Oct 2030 (estimated)
Last update
Apr 1, 2026

Study contacts

Mengling Zhong
Contact
mengling.zhong@dizalpharma.com
+86-21-61095852
Huang
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Birelentinib

Start the discussion